These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33866117)

  • 1. Microsimulation modeling of extended annual CT screening among lung cancer cases in the National Lung Screening Trial.
    Schreuder A; Mets OM; Schaefer-Prokop CM; Jacobs C; Prokop M
    Lung Cancer; 2021 Jun; 156():5-11. PubMed ID: 33866117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung cancer screening by nodule volume in Lung-RADS v1.1: negative baseline CT yields potential for increased screening interval.
    Silva M; Milanese G; Sestini S; Sabia F; Jacobs C; van Ginneken B; Prokop M; Schaefer-Prokop CM; Marchianò A; Sverzellati N; Pastorino U
    Eur Radiol; 2021 Apr; 31(4):1956-1968. PubMed ID: 32997182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model.
    Lu MT; Raghu VK; Mayrhofer T; Aerts HJWL; Hoffmann U
    Ann Intern Med; 2020 Nov; 173(9):704-713. PubMed ID: 32866413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model.
    Han SS; Erdogan SA; Toumazis I; Leung A; Plevritis SK
    Cancer Causes Control; 2017 Sep; 28(9):947-958. PubMed ID: 28702814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving selection criteria for lung cancer screening. The potential role of emphysema.
    Sanchez-Salcedo P; Wilson DO; de-Torres JP; Weissfeld JL; Berto J; Campo A; Alcaide AB; Pueyo J; Bastarrika G; Seijo LM; Pajares MJ; Pio R; Montuenga LM; Zulueta JJ
    Am J Respir Crit Care Med; 2015 Apr; 191(8):924-31. PubMed ID: 25668622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.
    Meza R; ten Haaf K; Kong CY; Erdogan A; Black WC; Tammemagi MC; Choi SE; Jeon J; Han SS; Munshi V; van Rosmalen J; Pinsky P; McMahon PM; de Koning HJ; Feuer EJ; Hazelton WD; Plevritis SK
    Cancer; 2014 Jun; 120(11):1713-24. PubMed ID: 24577803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing Lung Cancer Screening Strategies in a Nationally Representative US Population Using Transportability Methods for the National Lung Cancer Screening Trial.
    Robertson SE; Joyce NR; Steingrimsson JA; Stuart EA; Aberle DR; Gatsonis CA; Dahabreh IJ
    JAMA Netw Open; 2024 Jan; 7(1):e2346295. PubMed ID: 38289605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and Outcomes of Lung Cancers Detected on Low-Dose Lung Cancer Screening CT.
    Zhang EW; Shepard JO; Kuo A; Chintanapakdee W; Keane F; Gainor JF; Mino-Kenudson M; Lanuti M; Lennes IT; Digumarthy SR
    Cancer Epidemiol Biomarkers Prev; 2021 Aug; 30(8):1472-1479. PubMed ID: 34108138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT screening for lung cancer: alternative definitions of positive test result based on the national lung screening trial and international early lung cancer action program databases.
    Yip R; Henschke CI; Yankelevitz DF; Smith JP
    Radiology; 2014 Nov; 273(2):591-6. PubMed ID: 24955929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of the cancer risk management model lung cancer screening module.
    Flanagan WM; Evans WK; Fitzgerald NR; Goffin JR; Miller AB; Wolfson MC
    Health Rep; 2015 May; 26(5):11-8. PubMed ID: 25993046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival Following Detection of Stage I Lung Cancer by Screening in the National Lung Screening Trial.
    Gierada DS; Pinsky PF
    Chest; 2021 Feb; 159(2):862-869. PubMed ID: 32822676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial.
    Becker N; Motsch E; Trotter A; Heussel CP; Dienemann H; Schnabel PA; Kauczor HU; Maldonado SG; Miller AB; Kaaks R; Delorme S
    Int J Cancer; 2020 Mar; 146(6):1503-1513. PubMed ID: 31162856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting.
    Treskova M; Aumann I; Golpon H; Vogel-Claussen J; Welte T; Kuhlmann A
    BMC Med; 2017 Aug; 15(1):162. PubMed ID: 28838313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
    Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
    Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
    Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
    JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Jonas DE; Reuland DS; Reddy SM; Nagle M; Clark SD; Weber RP; Enyioha C; Malo TL; Brenner AT; Armstrong C; Coker-Schwimmer M; Middleton JC; Voisin C; Harris RP
    JAMA; 2021 Mar; 325(10):971-987. PubMed ID: 33687468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mean sojourn time and effectiveness of mortality reduction for lung cancer screening with computed tomography.
    Chien CR; Chen TH
    Int J Cancer; 2008 Jun; 122(11):2594-9. PubMed ID: 18302157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the National Lung Screening Trial (NLST) publication and Medicare Lung cancer screening payment on lung cancer incidence rates: An interrupted time series analysis.
    Emmerick ICM; Uy K; Guiab K; Powers M; Lou F; Lin P; Maxfield M; Voland R; Varlotto J
    J Cancer Policy; 2022 Mar; 31():100318. PubMed ID: 35559870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Airflow Limitation and Histology Shift in the National Lung Screening Trial. The NLST-ACRIN Cohort Substudy.
    Young RP; Duan F; Chiles C; Hopkins RJ; Gamble GD; Greco EM; Gatsonis C; Aberle D
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1060-7. PubMed ID: 26199983
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.